LAUSR

1 Pocaterra L, Jain S, Reddy R et al. Clinical course of erythema nodosum leprosum: an 11-year cohort study in Hyderabad. India. Am J Trop Med Hyg 2006; 74:868–79. 2 Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 1965; 6:303–6. 3 Walker SL, Balagon M, Darlong J et al. ENLIST 1: an international multi-centre cross-sectional study of the clinical features of erythema nodosum leprosum. PLOS Negl Trop Dis 2015; 9:e0004065. 4 Walker SL, Lebas E, Doni SN et al. The mortality associated with erythema nodosum leprosum in Ethiopia: a retrospective hospitalbased study. PLOS Negl Trop Dis. 2014; 8:e2690. 5 Narang T, Kaushik A, Dogra S. Apremilast in chronic recalcitrant erythema nodosum leprosum: a report of two cases. Br J Dermatol 2020; 182:1034–37. 6 Li H, Zuo J, Tang W. Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases. Front Pharmacol 2018; 9:1048. 7 da Silva CO, Dias AA, da Costa Nery JA et al. Neutrophil extracellular traps contribute to the pathogenesis of leprosy type 2 reactions. bioRxiv 2019: 602722 (preprint). Available at: https://www.biorxiv. org/content/10.1101/602722v1 (last accessed 4 September 2019). 8 Faber WR, Jensema AJ, Goldschmidt WF. Treatment of recurrent erythema nodosum leprosum with infliximab. N Engl J Med 2006; 355:739. 9 Crowley J, Thac i D, Joly P et al. Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol 2017; 77:310–17.e1. 10 Leprosy Mission Nepal. CC-11050 Trial in Nepalese patients with erythema nodosum leprosum. Available at: https://clinicaltria ls.gov/ct2/show/NCT03807362 (accessed 17 July 2019). 11 Chandler DJ, Hansen KS, Mahato B et al. Household costs of leprosy reactions (ENL) in rural India. PLOS Negl Trop Dis 2015; 9: e0003431. 12 United Nations. UN Sustainable Development Goals. Available at: https://www.un.org/sustainabledevelopment/health/ (accessed 17 July 2019).